PIK3CA and hematologic disorder: Since the p110δ PI3K was cloned and characterized (Chantry et al., 1997; Vanhaesebroeck et al., 1997b) an increasing catalog of evidence showing p110δ-isoform specific functions in hematopoietic cells have suggested p110δ as a potential therapeutic target in immunity, inflammation, and hematological malignancies (Rommel et al., 2007; Okkenhaug and Fruman, 2010; Rommel, 2010; Soond et al., 2010; Fruman and Rommel, 2011).